Consumer Alert: Pradaxa Blood Thinner Linked To Heart Attacks

A new study released January 9, 2012 found that Pradaxa carries an increased risk of heart attack compared with other anti-coagulant medications.

January 19, 2012

Pradaxa (dabigatran etexilate mesylate) is a blood thinning medication used to reduce the risk of stroke or serious blood clots in patients with non-valvular atrial fibrillation, the most common type of heart rhythm abnormality.[1]  Pradaxa was approved by the U.S. Food and Drug Administration in October 2010.  Pradaxa is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.  

A new study released January 9 found that Pradaxa carries an increased risk of heart attack compared with other anti-coagulant medications.[2]  The study found that patients taking Pradaxa have a 33% higher relative risk of heart attack or severe symptoms of heart disease than do patients taking other common treatments.[3]

The FDA is also investigating reports of serious bleeding events in patients taking Pradaxa.[4]  Case reports on Pradaxa have noted increased bleeding associated with advanced age, renal impairment, and low body weight.[5]  Bleeding can lead to serious injury or even fatal outcomes.  Bleeding may be a complication of anticoagulant therapies. However, the FDA is working to determine whether the reports of bleeding in patients taking Pradaxa are occurring more commonly than would be expected. [6] 

Robins Kaplan Miller and Ciresi LLP is investigating Pradaxa.  If you or someone you know has been injured or killed following use of Pradaxa and you wish to consult with a lawyer, please call us at 1-800-553-9910 or e-mail us by clicking on this link: contact us.


[1] http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm
[2] Uchino and Hernandez, Dabigatran Association With Higher Risk of Acute Coronary Events, Archives of Internal Medicine, published online 1/9/2012.
[3] Id.
[4] http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm
[5] Jacobs and Stessman, Dabigatran: Do We Have Sufficient Data?, Archives of Internal Medicine, published online 1/9/2012.
[6] http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm

Copyright 2012.  All rights reserved.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.

Disclaimer

Tara D. Sutton

Partner

Chair, National Mass Tort Group;
Member of Executive Board

Related Publications

May 24, 2022
Briefly: Seeking Fees and Costs While on Appeal
Eric Magnuson, Gregory Voshell - Minnesota Lawyer
May 19, 2022
11th Circ. Ban On Service Awards May Inhibit Class Actions
William Reiss, Dave Rochelson - Law360
May 13, 2022
Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
David Martinez, Zac Cohen - Los Angeles & San Francisco Daily Journal
May 5, 2022
Antitrust Law As A Tool Against Privacy Abuses
Law 360 - William Reiss and Matthew Geyer
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
Back to Top